Participation in clinical trials is especially encouraged.BINV-25 NCCN Guidelines Version 4.2020Invasive Breast CancerNCCN Guidelines IndexTable of ContentsDiscussion复发性或 IV 期 (M1) 疾病的系统治疗:ER 和/或 PR 阴性;HER2 阴性大多数患者将是多线全身治疗缓解晚期乳腺癌的候选者。每次重新评估时,临床...
Footnote ttt added:According to the 5th ESO-ESMO international consensus guidelines for advanced breast cancer visceral crisis is defined as: “severe organ dysfunction, as assessed by signs and symptoms, laboratory studies and rapid progression of disease. Viscera...
Footnote i revised: Patients with a known genetic predisposition to breast cancer may have an increased risk of contralateral or ipsilateral breast cancers after breast-conservation therapy.Risk reduction strategies including prophylactic mastectomies should be discus...
Footnote i revised: Patients with a known genetic predisposition to breast cancer may have an increased risk of contralateral or ipsilateral breast cancers after breast-conservation therapy.Risk reduction strategies including prophylactic mastectomies should be discussed. (Also for subsequent pages) 04 BINV...
●年轻人群的癌症生存者问题,也请参见NCCN青少年和年轻成人肿瘤指南和儿童肿瘤协作组生存者指南(www.survivorshipguidelines.org)。- Y# K( Q/ t2 _' g ●对于接受免疫治疗的癌症生存者,有必要对免疫介导的毒性进行持续监测。参见NCCN免疫治疗相关毒性管理指南。3 Y6 Y* ~, q# ~( | ...
Patients with a known genetic predisposition to breast cancer p53基因病理突变(利-弗劳梅尼综合征)(2B类)(参见NCCN遗传/家族高风险评定指南:乳腺癌、卵巢癌和胰腺癌) Pathologic p53 mutation (Li-Fraumeni syndrome) (category 2B) (See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovar...
Imaging, 3rd bullet added:For patients with germline mutations or family history of breast cancer, please refer to See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic 新增:治疗后监测 Added:Post treatment monitoring ...
1.Beitsch PD, Whitworth PW, Hughes K, et al: Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37:453-460, 2019 2.Yang S, Axilbund JE, O’Leary E, et al: Underdiagnosis of hereditary breast and ovarian cancer in Medicare...
1.Beitsch PD, Whitworth PW, Hughes K, et al: Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37:453-460, 2019 2.Yang S, Axilbund JE, O’Leary E, et al: Underdiagnosis of hereditary breast and ovarian cancer in Medicare...
Referral to a higher-resource-level provider with the best available resources, to provide the highest level of cancer care possible, is always an appropriate option for the patient. *Modified from Anderson BO and Carlson RW. Guidelines for improving breast health care in limited resource countries...